Prevention of Proliferative Diabetic Retinopathy and Cataract in SDT Rats with Aminoguanidine, an Anti-Advanced Glycation End Product Agent

Fumihiko Toyoda, Akihiro Kakehashi*, Ayumi Ota, Nozomi Kinoshita, Chiho Kambara, Hiroko Yamagami, Hiroyuki Tamemoto, Hiroto Ueba, Yoh Dobashi, San-e Ishikawa, Masanobu Kawakami and Yasunori Kanazawa

1Department of Ophthalmology, Jichi Medical University, Saitama Medical Center, Saitama, Japan
2Department of Integrated Medicine I, Jichi Medical University, Saitama Medical Center, Saitama, Japan
3Japanese Diabetes Foundation, Tokyo, Japan

Abstract: Advanced glycation end products (AGEs) play important roles in the development of ocular complications in diabetes mellitus. Spontaneously Diabetic Torii (SDT) rats have marked hyperglycemia and severe ocular complications. We evaluated the effect of anti-AGE agents, aminoguanidine and pyridoxamine, and an antioxidant, probucol, on the development of diabetic retinopathy (DR) and cataract in SDT rats. Experiment 1 included five SDT rats treated with aminoguanidine, four SDT rats treated with probucol, and four untreated control SDT rats. After age 55 weeks, we evaluated DR by fluorescein angiomicroscopy and pathological study and cataract by biomicroscopy. Experiment 2 included six SDT rats treated with pyridoxamine, and six SDT rats and 10 non-diabetic normal Sprague-Dawley (SD) rats not treated with pyridoxamine. Retinopathy and cataract were evaluated as in experiment 1. Urinary pentosidine and Maillard reaction product X (MRX) levels were measured for 40 weeks in each group. Experiment 1: Mature cataracts and DR developed in all untreated SDT rats; aminoguanidine prevented cataracts and DR (p<0.05, vs untreated SDT rats). Probucol had no effect. Experiment 2: Mature cataracts developed in all untreated SDT rats (p<0.001 vs normal SD rats [0/10]) and DR developed in 67% (p<0.01, vs normal SD rats [0/10, 0%]). Pyridoxamine did not prevent cataracts (6/6, 100%) or DR (4/6, 37%) (nonsignificant vs untreated SDT rats) in SDT rats. Urinary pentosidine levels were higher in untreated (0.12±0.07 μg/mg-Cre) and pyridoxamine-treated (0.12±0.05 μg/mg-Cre) SDT rats than normal SD rats (0.069±0.019 μg/mg-Cre), but not significantly so. Urinary MRX levels were significantly (p<0.01) lower in normal SD rats (17.5±9.6 μg/mg-Cre) compared with untreated SDT rats (163.0±107.0 μg/mg-Cre); pyridoxamine had no effect (149.0±66.5 μg/mg-Cre) (nonsignificant vs untreated SDT rats). Aminoguanidine but not pyridoxamine and probucol prevent DR and cataracts in SDT rats.

Keywords: Diabetes, diabetic retinopathy, cataract, advanced glycation end products (AGEs), SDT rat.

INTRODUCTION

Diabetic ocular complications, such as diabetic retinopathy (DR), cataract, and neovascular glaucoma, impair quality of life due to severe visual loss. DR, one of the most serious complications of diabetes mellitus, frequently leads to blindness [1-3]. Despite laser treatment and vitreous surgery, which significantly decrease the likelihood of blindness in patients with diabetes, DR still remains the most frequent cause of postnatal blindness. Proliferative diabetic retinopathy (PDR), the end stage of DR, is characterized by new vessel formation accompanied by fibrous tissue proliferation leading to vitreous hemorrhage, subsequent tractional retinal detachment, and visual loss. Recent studies have suggested that several metabolic disorders following long-term poor glycemic control, including increased polyol pathway activity [4, 5], activation of protein kinase C (PKC) [6-8], increased oxidative stress [9, 10], and accumulation of advanced glycation end products (AGEs) [11, 12], may underlie development of DR. If patients with diabetes are treated with intensive glycemic control from the early stage of the disease, the complications can be prevented. However, not all patients can be diagnosed with diabetes in its early stage or receive appropriate treatment. Moreover, many patients with diabetes do not monitor their blood glucose level in the early stage because of the absence of symptoms. In these situations, new drugs to prevent diabetic complications regardless of the glycemic control have been long desired. However, to test the effectiveness of drugs against PDR, an animal model of PDR is needed. Although numerous diabetic animal models have been described, none has spontaneously developing PDR that closely mimics human DR. We reported a new spontaneously diabetic Torii rat (SDT rat) with severe ocular complications [13, 14]. In the current study, we tested two anti-AGE agents, aminoguanidine and pyridoxamine, and an antioxidant,
probucol, in this rat model to evaluate the effects on ocular complications.

**Animals**

The SDT rat, a substrain of the Sprague-Dawley (SD) rat, spontaneously develops diabetes mellitus. In 1988, five male rats with polyuria and glucosuria were identified among 305 rats from an outbred colony of the Crl:CD (SD) strain (Charles River Japan, Inc., Kanagawa, Japan) of SD rats. After the 20th generation of sister-brother matings, the diabetic strain was established in 1997. The characteristics of this rat have been described previously [13, 14]. Briefly, male rats develop marked hyperglycemia (about 700 mg/dl) and glucosuria after 20 weeks of age. The cumulative incidence of diabetes is almost 100% by 40 weeks of age. Female rats also develop diabetes; however, it appears much later, i.e., after 45 weeks of age, and the cumulative incidence is only 35% even after 60 weeks of age. The survival rates of untreated male and female SDT rats up to 65 weeks are 93% and 97%, respectively. Mature diabetic cataracts are observed after 40 weeks of age in most male SDT rats. Large retinal folds mimicking a tractional retinal detachment and extensive fluorescein leakage around the optic disc are the most prominent findings of DR in old (mostly after 50 weeks of age) SDT rats. Young SDT rats (under 50 weeks of age) usually do not develop advanced DR.

**METHODS**

We performed two experiments to evaluate the effects of aminoguanidine, pyridoxamine, and probucol. The care and handling of all animals were in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.

**Experiment 1**

The SDT rats received regular chow until they developed diabetes, estimated by high blood glucose levels (>250 mg/dl.). After the rats were confirmed to be diabetic (mean age, 35 weeks), five SDT rats were treated with aminoguanidine (0.5 g/L in drinking water) and four SDT rats were treated with probucol (1% in pellets). Four SDT rats were left untreated. After 55 weeks of age, fluorescein angiomicroscopy and pathological study were performed, and cataract was evaluated in each group.

**Fluorescein Angiomicroscopy**

Fluorescein angiomicroscopy was performed after intracardiac injection of fluorescein-dextran (fluorescein isothiocyanate-dextran, Sigma, St. Louis, MO), using a modification of a previously reported method [13]. Under deep anesthesia induced by intraperitoneal injection of pentobarbital sodium (25 mg/kg body weight), 1 ml of phosphate buffered saline containing 50 mg of fluorescein-dextran was injected into the left ventricle of each animal. After 5 minutes, the right eye was enucleated for fluorescein microscopy and the left eye for histopathology. The retina was peeled from the eyecup and the entire retina was flat-mounted on a slide glass without fixation. A drop of aqueous mounting medium (Crystal/Mount, Biomedca Corp., Foster City, CA, USA) was applied over the retina and allowed to dry. The flat-mounted retina was examined by fluorescence microscopy (Nikon SMZ1500 with P-FLA fluorescence attachment, Nikon, Tokyo, Japan).

**Histopathology**

The eyes were enucleated for histopathology and placed in a fixative (a mixture of 2.5% paraformaldehyde and 1% glutaraldehyde in 0.15 M phosphate buffer) to avoid artificial retinal detachment. The fixed eyes were washed in 0.1% mol/l cacodylate buffer and embedded in paraffin. The paraffin block was sectioned to 4 μm and stained with hematoxylin and eosin for conventional histopathologic examination. The immunohistochemical procedures were based on the standard avidin-biotin horseradish peroxidase method using each antibody and developed with AEC Substrate Chromogen (DakoCytomation, Carpenteria, CA, USA). Carboxymethyl lysine (CML) was immunostained with a monoclonal antibody of CML (Trans Genic Inc., Kumamoto, Japan). Bovine serum was used as the primary antibody for negative control of the immunostaining.

**Biomicroscopy of Cataract**

The pupils were fully dilated with a topical ophthalmic solution containing tropicamide 5% and phenylephrine hydrochloride 5%, and the anterior segment including the lens was observed and photographed in both eyes of all rats.

**Experiment 2**

The SDT rats were treated as in experiment 1 except for the drugs studied. After the rats were confirmed to be diabetic, six SDT rats were treated with pyridoxamine (1 g/L in drinking water), and six control SDT rats and 10 non-diabetic normal SD rats were untreated. After 60 weeks of age, fluorescein angiomicroscopy and pathological study were performed and cataract was evaluated as described previously in each group. All rats were housed in metabolic cages for 40 weeks after the onset of diabetes, and a 24-h urine sample was collected. The urine samples were centrifuged at 1,700 xg for 10 min at 4° Celsius to obtain the supernatant. The urinary pentosidine level was measured by enzyme-linked immunosorbent assay (ELISA) and the urinary Maillard reaction product X (MRX) level was measured by high-performance liquid chromatography (HPLC). The ELISA and HPLC analyses were performed by Fushimi Pharmaceutical Co Ltd., Marugame, Japan. The pentosidine and MRX levels were corrected by the creatinine level in urine and expressed in micrograms per milligram of creatinine.

The prevalence rates of DR and cataract were evaluated by Fisher’s exact test of independence. The Student’s t-test and Mann-Whitney’s U test were used for comparisons between each group. The values are expressed as mean±SD, and p<0.05 was considered significant.

**RESULTS**

**Experiment 1**

Mature cataracts and DR developed in all animals in the untreated SDT rat group (4/4, 100%), but aminoguanidine prevented cataracts and DR (0/5, 0%) (p<0.05 by Fisher’s exact test). Probucol had no effect (4/4, 100%) (nonsignificant vs untreated SDT rats) (Fig. 1).
Immunohistochemical study showed less CML staining in the retina and posterior subcapsular space in aminoguanidine-treated eyes compared with probucol-treated eyes (Fig. 2).

**Experiment 2**

As in experiment 1, mature cataracts developed in all (6/6, 100%) untreated SDT rats (p<0.001 vs normal SD rats [0/10, 0%] by Fisher’s exact test) and DR developed in two thirds (4/6, 67%) (p<0.01, vs normal SD rats [0/10, 0%] by Fisher’s exact test).

**Fig. (1).** **Effect of aminoguanidine and probucol on diabetic cataract and retinopathy.** The top row shows the slit-lamp findings in the lens. The untreated control rat and the probucol-treated SDT rat have mature diabetic cataracts, whereas the aminoguanidine-treated SDT rat has minimal lens opacity. The bottom row shows the fluorescein angiomicroscopy findings. The untreated control rat and the probucol-treated SDT rat have extensive fluorescein leakage and narrowing of the capillaries around the optic disc. The aminoguanidine-treated SDT rat has no abnormalities.

**Fig. (2).** **Immunohistochemistry for CML in aminoguanidine- and probucol-treated SDT rats.** Left, the photographs show extensive staining for CML in the thickened retina and the subcapsular space of the lens in probucol-treated eyes. The magnified photograph shows extensive staining for CML in the inner retina (red arrow). Right, the photographs show less staining for CML in aminoguanidine-treated eyes. The magnified photograph shows no staining for CML in the lens and less staining for CML in the inner retina (red arrow).
Aminoguanidine, an Anti-Advanced Glycation End Product Agent

The Open Diabetes Journal, 2011, Volume 4

Fisher’s exact test). Pyridoxamine did not prevent cataracts in SDT rats (6/6, 100%) or DR (4/6, 37%) (nonsignificant vs untreated SDT rats) (Fig. 3).

Immunohistochemical study showed less staining of CML in the retina and posterior subcapsular space in normal SD rat eyes compared with SDT rat eyes treated with pyridoxamine and those not treated with pyridoxamine (Fig. 4).

The urinary pentosidine levels were not significantly higher in untreated (0.12±0.07 μg/mg-creatinine (Cre)) (p=0.13 by Mann-Whitney’s U-test) and pyridoxamine-treated (0.12±0.05 μg/mg-Cre) (p=0.06 by Student’s t-test) SDT rats than in normal SD rats (0.069±0.019 μg/mg-Cre) (Fig. 5).

Urinary MRX levels were significantly (p<0.01 by Mann-Whitney’s U-test) lower in the normal SD rats (17.5±9.6 μg/mg-Cre) compared with the untreated SDT rats (163.0±107.0 μg/mg-Cre). Pyridoxamine had no effect (149.0±66.5 μg/mg-Cre) (nonsignificant vs untreated SDT rats by Student’s t-test) (Fig. 6).

**DISCUSSION**

Ocular complications in diabetes, cataract, retinopathy, and neovascular glaucoma are thought to result from increased polyol pathway activity, activation of PKC,
increased oxidative stress, and accumulation of AGEs resulting from prolonged hyperglycemia. In advanced DR, retinal ischemia followed by neovascularization of the retina and/or of iris (neovascular glaucoma) could result in blindness. Among these mechanisms, AGE accumulation is one of the most important. While many compounds are AGEs, CML is a major AGE that affects the ocular complications in diabetes [15-17]. Hammes et al. reported that accumulation of CML is recognized even in early-phase DR and that increased CML accumulation is associated with progression of DR [18]. However, pentosidine is more important than CML in the development of diabetic nephropathy [16, 19, 20]. So pentosidine is thought to be a marker of nephropathy in patients with diabetes. MRX, a novel AGEs isolated from the hydrolysate of glycated proteins [21], is a good biomarker for detecting oxidative stress produced during the Maillard reaction. In our experiment, pyridoxamine did not decrease pentosidine and MRX in SDT rats.

Several clinical studies have reported that the pentosidine level is related more closely to nephropathy than retinopathy [16, 22]. Those correlations strongly suggested that CML is the most important AGE-induced neovascularization in the eye. Pyrraline and pentosidine may be other causes of ocular
complications. Our other publication on immunohistochemical study of SDT rats by Toyoda et al. (Toyoda et al. Accumulation of AGES and VEGF in Eyes of SDT Rats, TODJ) in the same issue also showed that CML plays an important role in the development of PDR in SDT rats, while pyrraline and pentosidine may not.

Aminoguanidine is a hydrazine compound that prevents formation of AGE by competitive inhibition. Because the early (Amadori-type) glycosylation products have a stronger affinity for aminoguanidine than for lysine-aminogroups of proteins, they bind to aminoguanidine, inducing formation of unreactive substitutes that cannot crosslink with other similar proteins or trap plasma proteins with which they may be in contact [23]. Moreover, aminoguanidine prevents oxidative modification of low-density lipoprotein [24]. However, pyridoxamine, a member of the B6 vitamer family, is a potent scavenger of reactive carbonyls that inhibits the late stages of glycation reactions that lead to AGE formation [25]. Stitt et al. reported that pyridoxamine inhibits development of DR in streptozotocin (STZ)-induced diabetic rats [26]. In contrast to SDT rats, STZ-induced diabetic rats have only some microaneurysms and thickening of the basement membrane of the retinal capillaries without proliferative changes. However, SDT rats have extensive vascular hyperpermeability and tractional retinal detachment with thickening around the optic disc. Hyperglycemia is more extensive in SDT rats than STZ-induced diabetic rats [14]. Pyridoxamine may regulate DR but may not be effective in serious cases like SDT rats.

In conclusion, aminoguanidine has a strong inhibitory effect on diabetic ocular complications in SDT rats, but pyruvul and pyridoxamine do not have the same effect. CML seems to be an important AGE in the development of diabetic ocular complications.

REFERENCES